Prevention and treatment of pancreatic cancer by curcumin in combination with omega-3 fatty acids

Nutrition and Cancer

Volumn 60, Issue SUPPL. 1, 2008, Pages 81-89

  Swamy, Malisetty V ^a   Citineni, Bhargava ^a   Patlolla, Jagan M R ^a   Mohammed, Altaf ^a   Zhang, Yuting ^a   Rao, Chinthalapally V ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b BRC 1203 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 LIPOXINASE; CURCUMIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; FISH OIL; INDUCIBLE NITRIC OXIDE SYNTHASE; OXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; TUMOR VOLUME;

ANIMALS; APOPTOSIS; ARACHIDONATE 5-LIPOXYGENASE; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLOOXYGENASE 2; FATTY ACIDS, OMEGA-3; FISH OILS; HUMANS; MICE; NITRIC OXIDE SYNTHASE TYPE II; PANCREATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS; MUS MUSCULUS; ZEA MAYS;

EID: 55949119550     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580802416703     Document Type: Conference Paper

References (60)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al.: Cancer statistics, 2007. CA Cancer J Clin 57, 43-66, 2007.
2. Hochster HS, Haller DG, de GA, Berlin JD, Philip PA, et al.: Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer 107, 676-685, 2006.
3. Diamantidis M, Tsapournas G, Kountouras J, and Zavos C: New aspects of regulatory signaling pathways and novel therapies in pancreatic cancer. Curr Mol Med 8, 12-37, 2008.
4. Welsch T, Kleeff J, and Friess H: Molecular pathogenesis of pancreatic cancer: advances and challenges. Curr Mol Med 7, 504-521, 2007.
5. McKay CJ, Glen P, and McMillan DC: Chronic inflammation and pancreatic cancer. Best Pract Res Clin Gastroenterol 22, 65-73, 2008.
6. Li L, Aggarwal BB, Shishodia S, Abbruzzese J, and Kurzrock R: Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101, 2351-2362, 2004.
7. Kasper HU, Wolf H, Drebber U, Wolf HK, and Kern MA: Expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic adenocarcinoma: correlation with microvessel density. World J Gastroenterol 10, 1918-1922, 2004.
8. Juuti A, Louhimo J, Nordling S, Ristimäki A, and Haglund C: Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol 59, 382-386, 2006.
9. Hennig R, Grippo P, Ding XZ, Rao SM, Buchler MW, et al.: 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res 65, 6011-6016, 2005.
10. Surh YJ, Chun KS, Cha HH, Han SS, Keeum YS, et al.: Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 480-481, 243-268, 2001.
11. Bharti AC, Donato N, and Aggarwal BB: Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171, 3863-3871, 2003.
12. Aggarwal S, Takada Y, Singh S, Myers JN, and Aggarwal BB: Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer 111, 679-692, 2004.
13. Menon VP and Sudheer AR: Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 595, 105-125, 2007.
14. Rao CV, Simi B, and Reddy BS: Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 14, 2219-2225, 1993.
15. Rao CV: Regulation of COX and LOX by curcumin. Adv Exp Med Biol 595, 213-226, 2007.
16. Rao CV, Rivenson A, Simi B, and Reddy BS: Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 55, 259-266, 1995.
17. Strimpakos AS and Sharma RAL: Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxide Redox Signal 10, 511-545, 2008.
18. Khor TO, Keum YS, Lin W, Kim JH, Hu R, et al.: Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res 66, 613-621, 2006.
19. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, et al.: Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 11, 7490-7498, 2005.
20. Shishodia S, Chaturvedi MM, and Aggarwal BB: Role of curcumin in cancer therapy. Curr Probl Cancer 31, 243-305, 2007.
21. Granados S, Quiles JL, Gil A, Ramirez-Tortosa MC: Dietary lipids and cancer. Nutr Hosp 21 (2 Suppl), 42-54, 2006.
22. Simopoulos AP: Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed Pharmacother 60, 502-507, 2006.
23. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A: Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 79, 935-945, 2004.
24. Smith WL: Cyclooxygenases, peroxide tone and the allure of fish oil. Curr Opin Cell Biol 17, 174-182, 2005.
25. Kato T, Hancock RL, Mohammadpour H, McGregor B, Manolo Khaiboullina, et al.: Influence of omega-3 fatty acids on the growth of human colon carcinoma in nude mice. Cancer Lett 187, 169-177, 2002.
26. Kelavkar UP, Hutzley J, Dhir R, Kim P, Allen KG, et al.: Prostate tumor growth and recurrence can be modulated by the omega-6:omega-3 ratio in diet: athymic mouse xenograft model simulating radical prostatectomy. Neoplasia 8, 112-124, 2006.
27. Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, et al.: Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res 12, 4662-4670, 2006.
28. Reddy BS, Patlolla JM, Simi B, and Rao CV: Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids. Cancer Res 65, 8022-8027, 2005.
29. Xia S, Lu Y, Wang J, He C, Hong S, et al.: Melanoma growth is reduced in fat-1 transgenic mice: impact of omega-6/omega-3 essential fatty acids. Proc Natl Acad Sci USA 103, 12499-12504, 2006.
30. Gregor JI, Heukamp I, Kilian M, Kiewert C, Schimke I, et al.: Does enteral nutrition of dietary polyunsaturated fatty acids promote oxidative stress and tumor growth in ductal pancreatic cancer? Experimental trial in Syrian hamster. Prostaglandins Leukot Essent Fatty Acids 74, 67-74, 2006.
31. Heukamp I, Gregor JI, Kilian M, Kiewert C, Jacobi CA, et al.: Influence of different dietary fat intake on liver metastasis and hepatic lipid peroxidation in BOP-induced pancreatic cancer in Syrian hamsters. Pancreatology 6, 96-102, 2006.
32. Merendino N, Loppi B, D'Aquino M, et al.: Docosahexaenoic acid induces apoptosis in the human PaCa-44 pancreatic cancer cell line by active reduced glutathione extrusion and lipid peroxidation. Nutr Cancer 52, 225-233, 2005.
33. Shirota T, Haji S, Yamasaki M, Iwasaki T, Hidaka T, et al.: Apoptosis in human pancreatic cancer cells induced by eicosapentaenoic acid. Nutrition 21, 1010-1017, 2005.
34. Rao CV and Reddy BS: NSAIDs and chemoprevention. Curr Cancer Drug Targets 4, 29-42, 2004.
35. Sawai H, Okada Y, Kazanjian K, Kim J, Hasan S, et al.: The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res 65, 11536-11544, 2005.
36. Swamy MV, Cooma I, Patlolla JM, Simi B, Reddy BS, et al.: Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment. Mol Cancer Ther 3, 215-221, 2004.
37. Rao CV, Reddy BS, Steele VE, Wang CX, Liu X, et al.: Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther 5, 1530-1538, 2006.
38. Rao CV, Hirose Y, Indranie C, and Reddy BS: Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids. Cancer Res 61, 1927-1933, 2001.
39. Lev-Ari S, Zinger H, Kazanov D, Yona D, et al.: Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 106, 2503-2513, 2006.
40. Kunnumakkara AB, Guha S, Krishnan S, Diagaradja P, et al.: Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67, 3853-3861, 2007.
41. Sun M, Estrov Z, Ji Y, Coombes KR, et al.: Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 7, 464-473, 2008.
42. Mozaffarian D and Rimm EB: Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 296, 1885-1899, 2006.
43. Chen YQ, Berquin IM, Daniel LW, et al.: Omega-3 fatty acids and cancer risk. JAMA 296, 282, 2006.
44. MacLean CH, Newberry SJ, Mojica WA, et al.: Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA 295, 403-415, 2006.
45. Hardman WE: (n-3) fatty acids and cancer therapy. J Nutr 134, 3427S-3430S, 2004.
46. Barber MD, Fearon KC, Tisdale MJ, et al.: Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. Nutr Cancer 40, 118-124, 2001.
47. Moses AW, Slater C, Preston T, et al.: Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 90, 996-1002, 2004.
48. Calviello G, Di NF, Gragnoli S, et al.: n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway. Carcinogenesis 25, 2303-2310, 2004.
49. Horia E and Watkins BA: Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells. Carcinogenesis 28, 809-815, 2007.
50. Hughes-Fulford M, Chen Y, and Tjandrawinata RR: Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells. Carcinogenesis 22, 701-707, 2001.
51. Funahashi H, Satake M, Hasan S, Sawai H, et al.: Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth. Pancreas 36, 353-362, 2008.
52. Lev-Ari S, Vexler A, Starr A, et al.: Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Invest 25, 411-418, 2007.
53. Lev-Ari S, Zinger H, Kazanov D, Yona D, et al.: Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomed Pharmacother 59 (2 Suppl), S276-S280, 2005.
54. Yang P, Chan D, Felix E, et al.: Formation and antiproliferative effect of prostaglandin E(3) from eicosapentaenoic acid in human lung cancer cells. J Lipid Res 45, 1030-1039, 2004.
55. Lin JK: Molecular targets of curcumin. Adv Exp Med Biol 595, 227-243, 2007.
56. Thangapazham RL, Sharma A, and Maheshwari RK: Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J 8, 443-449, 2006.
57. Aggarwal BB and Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71, 1397-1421, 2006.
58. Zolota V, Tsamandas AC, Aroukatos P, et al.: Expression of cell cycle inhibitors p21, p27, p14 and p16 in gliomas: correlation with classic prognostic factors and patients' outcome. Neuropathology 28, 35-42, 2008.
59. Dang CX, Han Y, Qin ZY, Wang YJ: Clinical significance of expression of p21 and p53 proteins and proliferating cell nuclear antigen in pancreatic cancer. Hepatobiliary Pancreat Dis Int 1, 302-305, 2002.
60. Ghaneh P, Kawesha A, Evans JD, and Neoptolemos JP: Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg 9, 1-11, 2002.